Related Experiment Videos
Cyclophosphamide-induced changes in the MRL-lpr/lpr mouse: effects upon cellular composition, immune function, and
Clinical Immunology and Immunopathology
|January 1, 1984
Summary
Cyclophosphamide treatment reversed autoimmune disease in MRL-lpr/lpr mice by eliminating abnormal T cells. This suggests the disease is reversible, offering potential therapeutic insights.
Area of Science:
- Immunology
- Autoimmune Diseases
- Pharmacology
Background:
- MRL-lpr/lpr mice exhibit severe lymphadenopathy and immune dysfunction due to excessive T cell proliferation.
- The intrinsic and irreversible nature of this autoimmune disease process requires investigation.
Purpose of the Study:
- To determine if the autoimmune disease in MRL-lpr/lpr mice is reversible.
- To evaluate the efficacy of cyclophosphamide in treating established disease.
Main Methods:
- Administration of cyclophosphamide to 16-week-old MRL-lpr/lpr mice.
- Flow cytometry analysis of lymphoid cellular composition.
- Assessment of immune responses to sheep red blood cells and concanavalin A.
- Evaluation of clinical parameters including survival, arthritis, organomegaly, renal histology, and autoantibody levels.
Main Results:
- Cyclophosphamide treatment normalized T and B cell populations in lymph nodes.
- Immune responses to antigens and mitogens were restored to normal levels.
- Treated mice showed prolonged survival, reduced disease severity (arthritis, lymphadenopathy, splenomegaly), improved kidney histology, and lower autoantibody levels.
Conclusions:
- The autoimmune disease and associated immune abnormalities in MRL-lpr/lpr mice are reversible.
- Selective elimination of abnormal dull Ly 1+ T cells by cyclophosphamide is a key factor in disease reversal.
- This study highlights the potential of immunomodulatory therapies for autoimmune conditions.